The global vaccine market grew at a CAGR of around 8% during 2014-2019 reaching US$ 37 Billion in 2019. From a public health perspective, vaccines represent among the most important inventions in human history. A vaccine refers to a biological component that stimulates the production of antibodies against several pathogens present in the body. It is generally produced by using disease-causing agents and chemical drugs that act as antigens in disease prevention. Vaccines are primarily available in the form of conjugate vaccines, inactivated vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. They help in preventing various life-threatening diseases, including measles, polio, diphtheria, meningitis, influenza, tetanus, rotavirus, hepatitis, etc. As a result, vaccines are widely adopted for several immunization procedures, across hospitals, clinics, and vaccination centers, and for research purposes in academic and clinical laboratories.
The high prevalence of several infectious diseases is primarily driving the demand for vaccines. The growing consumer awareness towards effective immunization for eradicating various infections is further catalyzing the market growth. Moreover, the introduction of several vaccination programs by governments across various endemic regions is also propelling the demand for vaccines. Additionally, the market is also driven by the growing number of child deaths due to various infectious diseases, such as hepatitis, polio, measles, rubella, etc., particularly across the under-developed countries. The increasing involvement of several global organizations, such as the WHO, UNICEF, World Bank, Bill & Melinda Gates Foundation, etc. for developing adequate vaccination facilities in the endemic regions, is further catalyzing the product demand. Several pharmaceutical companies are focusing on the development of new and improved vaccines by accelerating the clinical trials of various pipeline drugs. Extensive R&D activities pertaining to the immunization of several fatal diseases, such as AIDS, Ebola, Hepatitis C, paratyphoid fever, etc., are also expected to fuel the market growth. The outbreak of the COVID-19 pandemic, leading to around half a million global deaths (as of June 2020), is currently creating opportunities for a novel vaccine against COVID-19. Looking forward, IMARC Group expects the global vaccine market to reach US$ 57 Billion by 2025.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, technology, patient type, indication, administration, route of administration, product type, treatment type, end-user, and distribution channel.
Breakup by Technology:
Breakup by Patient Type:
Breakup by Indication:
Breakup by Route of Administration:
Breakup by Product Type:
Breakup by Treatment Type:
Breakup by End User:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, Bharat Biotech International, Bavarian Nordic A/S, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Johnson & Johnson, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation), Novavax Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi Pasteur SA (Sanofi SA), Serum Institute of India Pvt. Ltd. and Takeda Pharmaceutical Company Limited.
The global vaccine market was worth around US$ 37 Billion in 2019.
According to the estimates by IMARC Group, the global vaccine market will exhibit moderate growth during 2020-2025.
The rising prevalence of infectious diseases and the growing awareness about effective immunization are among the significant factors impelling the global vaccine market growth.
The increasing focus on the development of new and improved vaccines, along with the introduction and continual launch of various vaccination programs by governments of numerous countries, is bolstering the market growth.
Due to the rapid spread of the coronavirus disease (COVID-19) and the increasing death rate, there is an urgent need to develop novel vaccines to provide effective treatment to patients. Consequently, several organizations are engaging in research and development (R&D) activities, which, in turn, is positively influencing the market growth.
Based on the technology, the market has been classified into conjugate, inactivated and subunit, live attenuated, recombinant, toxoid, and other vaccines.
On the basis of the patient type, the market has been bifurcated into pediatric and adults.
The market has been analyzed on the basis of the indication into bacterial diseases [meningococcal, pneumococcal, diphtheria/tetanus/pertussis (DPT), tuberculosis, Hemophilus influenzae (Hib), typhoid and others] and viral diseases [Hepatitis, influenza, human papillomavirus (HPV), measles/mumps/rubella (MMR), rotavirus, herpes zoster, varicella, Japanese encephalitis, rubella, polio, rabies, dengue and others].
Based on the route of administration, the market has been categorized into intramuscular and subcutaneous administration, oral administration and others.
On the basis of the product type, the market has been divided into multivalent and monovalent vaccines.
The market has been analyzed on the basis of the treatment type into preventive and therapeutic vaccines.
Based on the end user, the market has been classified into hospitals, clinics, vaccination centers, academic and research institutes, and others.
On the basis of the distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, institutional sales and others.
Region-wise, the market has been classified into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia and others); Europe (the United Kingdom, Germany, France, Italy, Spain, Russia and others); Latin America (Brazil, Mexico and others); and the Middle East and Africa (Turkey, GCC Countries, Israel and others).
Leading industry players are Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bharat Biotech International Ltd., Bavarian Nordic A/S, CSL Ltd., Daiichi Sankyo Company, Limited, Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation), Novavax Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi Pasteur SA (Sanofi SA), Serum Institute of India Pvt. Ltd. and Takeda Pharmaceutical Company Limited.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )
Drop us an email at